Business Context and Reporting Period
Company: 22nd Century Group, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: October 17, 2023
Event: Entry into a Material Definitive Agreement for a registered public offering of securities.
Key Financial Metrics and Transaction Details
This filing details a capital raise rather than operational financial results. Key transaction metrics include:
- Gross Proceeds: Approximately $5.25 million.
- Offering Price: $0.525 per share (combined with two Common Warrants).
- Securities Issued:
- 7,600,000 shares of Common Stock.
- 20,000,000 Common Warrants (Exercise Price: $0.525; Term: 5 years).
- 2,400,000 Pre-Funded Warrants (Exercise Price: $0.0001).
- Placement Agent Fees: 7% of aggregate gross proceeds plus 7% of aggregate exercise price received on solicited Common Warrants.
- Expense Reimbursement: Up to $125,000 for legal fees.
- Placement Agent Warrants: Warrants to purchase up to 1,000,000 shares at an exercise price of $0.65625 (125% of public offering price).
Use of Proceeds: General corporate purposes.
Material Changes and Outlook
Material Changes: The Company entered into a Securities Purchase Agreement to raise capital. The filing does not provide comparative financial data (revenue, profit, cash flow) for the current period versus prior periods as this is a transactional report, not a periodic financial statement.
Outlook and Management Commentary: The Offering is expected to close on or about October 19, 2023, subject to customary closing conditions. The Company intends to utilize the net proceeds for general corporate purposes.
Risks and Contingencies: The transaction is subject to satisfaction of customary closing conditions. The Placement Agent Warrants cannot be exercised until the Company increases its authorized shares of common stock.
Investor Verification Checklist
- Verify the final closing date of the Offering (expected October 19, 2023).
- Confirm the final number of shares and warrants sold to calculate total dilution.
- Review the final prospectus supplement for any changes to the offering terms.
- Monitor the Company's filings for the increase in authorized shares required to allow exercise of Placement Agent Warrants.
- Assess the impact of the 7% placement agent fees and expense reimbursements on net proceeds.